I think the sector is setting up well if we can break above the $138 level in the near term. Yes, we had a couple days of weakness earlier this week but the recent strength (modest as it has been) is setting up that weakness as a potential higher low. This become more likely if […]
Not a lot going on in the sector, which makes it a little tough to write about but it does provide a way to figure out the underlying sentiment. Of course, it seems like the underlying sentiment is basically flat. Not much movement one way or the other so we are in a low volume […]
Not a lot going on in the sector today. We had that pullback yesterday and it puts us in an odd space. There is not a really clear place to bounce with the $131.5 or so level perhaps a point. We need to find some point above the recent lows to bounce and move to […]
It looked like we could have gotten some momentum but it was not quite able to continue. It was not stock specific but pretty broad based. It is not as if it was a particularly bad day but that momentum that was building that I thought could get us to the $140-1 level on the […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.